Published in Circ Res on May 03, 2002
Interferon-gamma and the interferon-inducible chemokine CXCL10 protect against aneurysm formation and rupture. Circulation (2009) 1.40
MMP induction and inhibition in myocardial infarction. Heart Fail Rev (2004) 1.35
Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med (2007) 1.32
Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases. Pathol Int (2010) 1.29
Biomarkers of extracellular matrix metabolism (MMP-9 and TIMP-1) and risk of stroke, myocardial infarction, and cause-specific mortality: cohort study. PLoS One (2011) 1.26
Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. Thromb Haemost (2009) 1.24
Periods of low atmospheric pressure are associated with high abdominal aortic aneurysm rupture rates in Northern Ireland. Ulster Med J (2005) 1.15
Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. EXS (2012) 1.03
Comparison of MMP-2 and MMP-9 secretion from T helper 0, 1 and 2 lymphocytes alone and in coculture with macrophages. Immunology (2007) 1.00
Experimental models of abdominal aortic aneurysms. Open Cardiovasc Med J (2010) 0.94
Catalase overexpression in aortic smooth muscle prevents pathological mechanical changes underlying abdominal aortic aneurysm formation. Am J Physiol Heart Circ Physiol (2011) 0.93
Accelerated aneurysmal dilation associated with apoptosis and inflammation in a newly developed calcium phosphate rodent abdominal aortic aneurysm model. J Vasc Surg (2012) 0.88
Matrix metalloproteinases and cardiovascular diseases. Hippokratia (2009) 0.88
Matrix metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease in the atherosclerosis risk in communities (ARIC) study. Tex Heart Inst J (2008) 0.84
Pentosan polysulfate inhibits atherosclerosis in Watanabe heritable hyperlipidemic rabbits: differential modulation of metalloproteinase-2 and -9. Lab Invest (2011) 0.82
Tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphisms in a Caucasian population with abdominal aortic aneurysm. World J Surg (2007) 0.82
Cysteine protease cathepsins and matrix metalloproteinases in the development of abdominal aortic aneurysms. Future Cardiol (2013) 0.81
Differential effects of tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 on atherosclerosis and monocyte/macrophage invasion. Cardiovasc Res (2015) 0.78
Matrix metalloproteinases: are they antiatherogenic but proaneurysmal? Circ Res (2002) 0.77
Recent Advances in the Development of Experimental Animal Models Mimicking Human Aortic Aneurysms. Vasc Specialist Int (2015) 0.75
Ascending thoracic aortic aneurysms protect against myocardial infarctions. Int J Angiol (2014) 0.75
Ascending Aortic Proaneurysmal Genetic Mutations with Antiatherogenic Effects. Int J Angiol (2015) 0.75
Pathological and molecular analyses of atherosclerotic lesions in ApoE-knockout mice. Med Mol Morphol (2017) 0.75
Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders. Prog Mol Biol Transl Sci (2017) 0.75
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996) 18.47
Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature (1998) 11.61
Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell (1999) 7.33
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med (2001) 6.73
Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature (1983) 5.27
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med (1999) 4.85
Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet (2001) 4.66
Physiological consequences of loss of plasminogen activator gene function in mice. Nature (1994) 4.40
Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med (1999) 4.33
Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem (1982) 3.95
Molecular mechanisms of blood vessel growth. Cardiovasc Res (2001) 3.94
On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost (1980) 3.44
Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet (1997) 3.40
Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. Gene (1999) 3.00
Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost (2006) 2.81
Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem (1981) 2.80
Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med (2001) 2.66
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med (1998) 2.54
Role of tissue factor in embryonic blood vessel development. Nature (1996) 2.54
Total inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol (2000) 2.53
Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome. Nat Med (2001) 2.46
Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood (2000) 2.44
Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc Natl Acad Sci U S A (2001) 2.42
Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation (1995) 2.38
Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation (1998) 2.32
Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest (1993) 2.20
Transcription factor hepatocyte nuclear factor 6 regulates pancreatic endocrine cell differentiation and controls expression of the proendocrine gene ngn3. Mol Cell Biol (2000) 2.11
Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest (1993) 2.08
Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol (2001) 2.06
Basic and clinical aspects of fibrinolysis and thrombolysis. Blood (1991) 2.04
Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost (1981) 1.98
Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest (1985) 1.97
Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation (1999) 1.97
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol (2001) 1.94
Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation (1997) 1.91
Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol (2001) 1.89
On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem (1978) 1.86
Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood (1998) 1.81
Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem (1988) 1.77
New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost (2008) 1.73
Molecular mechanism of physiological fibrinolysis. Nature (1978) 1.71
On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen. Biochim Biophys Acta (1979) 1.69
Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood (1988) 1.68
Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci U S A (1996) 1.66
Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem (1976) 1.66
Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol (2000) 1.64
Angiogenesis and development of adipose tissue. Mol Cell Endocrinol (2009) 1.63
Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet (1985) 1.60
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med (1991) 1.58
Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med (1984) 1.57
Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein. J Biol Chem (1980) 1.56
On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. J Thromb Haemost (2005) 1.55
Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest (1998) 1.55
Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. J Clin Invest (2005) 1.55
Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation (1986) 1.55
Mice lacking the gene encoding tissue-type plasminogen activator show a selective interference with late-phase long-term potentiation in both Schaffer collateral and mossy fiber pathways. Proc Natl Acad Sci U S A (1996) 1.54
Generation and characterization of urokinase receptor-deficient mice. J Clin Invest (1996) 1.54
Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice. J Thromb Haemost (2005) 1.53
Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol (1990) 1.51
Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature (1997) 1.50
Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol (1998) 1.48
Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase. Circulation (1995) 1.47
Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res (1984) 1.46
Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature (1981) 1.45
Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis. Circulation (1990) 1.45
Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor-1 (PAI-1). J Thromb Haemost (2004) 1.45
Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost (1987) 1.44
Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation. Circulation (1991) 1.44
Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest (1997) 1.44
A mouse model for Zellweger syndrome. Nat Genet (1997) 1.43
Intravascular coagulation in liver disease. Annu Rev Med (1974) 1.40
Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor. J Clin Invest (1984) 1.40
Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am J Pathol (1997) 1.40
Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ann N Y Acad Sci (2000) 1.40
Intravenous thrombolysis with recombinant staphylokinase versus tissue-type plasminogen activator in a rabbit embolic stroke model. Stroke (1997) 1.39
Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Curr Top Microbiol Immunol (1999) 1.38
Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med (1997) 1.38
Matrix metalloproteinase inhibition impairs adipose tissue development in mice. Arterioscler Thromb Vasc Biol (2002) 1.37
Molecular analysis of blood vessel formation and disease. Am J Physiol (1997) 1.37
Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem (1982) 1.35
Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation (1989) 1.35
Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells. Circulation (2003) 1.35
Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. Am J Pathol (2000) 1.33
Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. J Clin Invest (1983) 1.31
Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism (1986) 1.30
Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis (1988) 1.30
Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma. Eur J Biochem (1977) 1.29
Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. J Biol Chem (1983) 1.29